Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125).
1. Please describe the FLAURA trail and its reported results? (0:04)
2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients with NSCLC? (3:00)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Raffaele Califano has acted as a consultant and advisor for AstraZeneca and BMS.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Lung Cancer
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Catherine A. Shu, ASCO 2022: Updated results from the CHRYSALIS-2 of amivantamab and lazertinib in patients with advanced NSCLC
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen. The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!